The Heart of the Matter – Is EMPA-REG a Game Changer for Diabetes Management?

November 19, 2015

The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) study sought to determine the effects of empagliflozin on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for CVD. Does the evidence from the EMPA-REG OUTCOME study coupled with the other benefits of SGLT2 inhibitors (reduction in weight and blood pressure, mild adverse effects) make empagliflozin the preferred second-line agent from the treatment of type 2 diabetes? 

00:0000:00

Managing Direct Oral Anticoagulants – What’s Our Role?

September 18, 2015

Many clinicians are questioning the role pharmacists play in anticoagulation therapy management as direct oral anticoagulants (DOACs) increasingly replace warfarin for a variety of indications. A recent study examined medication adherence and therapy management practices at Veterans Health Administration (VHA) patient care sites. Although this study does not have all the answers, it does reveal the importance of patient selection and ongoing patient monitoring – potentially key roles for pharmacists.

00:0000:00

PCSK9 Inhibitors: Blockbusters or Bust?

September 5, 2015

Two new mAbs, alirocumab and evolocumab, have been approved to treat elevated cholesterol when added to maximally tolerated statin therapy in patients with familial hypercholesterolemia or history of atherosclerotic cardiovascular disease (ASCVD). This new class of drugs, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is considered to be the biggest breakthrough in cholesterol treatment since statins were approved 3 decades ago. But are they worth it?

00:0000:00

CVD Risk Scores - Are They Accurate?

July 28, 2015

How well do cardiovascular disease risk calculators really perform?  Do they over or underestimate risk?  Should we rely on them to make treatment decisions?

00:0000:00

Anticoagulation Bridge Therapy - Risks and Benefits Examined

April 24, 2015

The ORBIT-AF study raises questions about anticoagulation therapy bridging practices.  Do the risks outweigh the benefits?

00:0000:00